AstraZeneca's Fasenra hit with FDA rejection, falling further behind GSK's Nucala in nasal polyps
March 14, 2022
AstraZeneca’s Fasenra hit with FDA rejection, falling further behind GSK’s Nucala in nasal polyps
aliu
Mon, 03/14/2022 – 09:22
Source link